Guggenheim Reiterates Buy Rating on Adaptive Biotechnologies
Guggenheim reaffirms its bullish stance on Adaptive Biotechnologies with a $22 price target, a 4.61% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Adaptive Biotechnologies (ADPT) with a $22 price target on June 29, 2026.
- Guggenheim's $22 price target implies 4.61% upside from Adaptive Biotechnologies Corporation's ($ADPT) current $21.03 share price.
- Shares of ADPT traded near $20.96 on Monday, with the company having a market cap of about $3.35 billion.
- Insiders, including Chief Scientific Officer Harlan Robins, sold shares under planned transactions in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim has reaffirmed its bullish stance on Adaptive Biotechnologies Corporation (NasdaqGS: ADPT), maintaining a buy rating with a $22 price target. This update came on June 29, 2026, from analyst Subbu Nambi. Shares of Adaptive traded around $20.96 on Monday.
Adaptive Biotechnologies Corporation Stock Down 16.5%
As of Monday, shares of Adaptive Biotechnologies were trading near $20.96. The company, which operates in the healthcare sector and specializes in diagnostics and research, has a market cap of approximately $3.35 billion. Adaptive Biotechnologies is not currently profitable, with a forward P/E ratio reflecting this. The stock's 52-week range has been between $9.96 and $21.01, with recent averages of $15.32 over 50 days and $15.62 over 200 days. The company's financial health includes a current ratio of 3.35 and a quick ratio of 3.08, though it carries a debt-to-equity ratio of 92.84.
$ADPT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its latest financial report, Adaptive Biotechnologies reported revenue of $295.4 million, marking a growth of 35.1%. Despite this, the company posted a net margin of -16.82% and a return on equity of -23.96%, indicating ongoing profitability challenges. The next earnings release is scheduled for August 4, 2026.
Insider Buying and Selling at Adaptive Biotechnologies Corporation
In June 2026, several insiders executed planned sales of Adaptive Biotechnologies shares. Chief Scientific Officer Harlan Robins sold 6,160 shares on June 16 at an average price of $18.01, and 100,000 shares on June 15 at $17.37. Chief Commercial Officer Susan Bobulsky sold 5,000 shares on June 11 at $19.00. Additionally, Chief People Officer Francis Lo sold shares on June 4, including a planned sale of 39,741 shares at $17.49 and an unplanned purchase of 19,521 shares at $8.85.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Adaptive Biotechnologies, setting a price target of $22. Morgan Stanley also maintained a hold rating with an $18 target as of May 12, 2026. JP Morgan and TD Cowen both reiterated buy ratings in early May, with targets of $19 and $21, respectively. The consensus among analysts is a strong buy, with a mean target price of $20.29 based on seven opinions.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a Seattle-based company in the healthcare sector, focusing on diagnostics and research. Founded in 2009, the company develops an immune medicine platform for diagnosing and treating various diseases. Its immunosequencing platform combines proprietary chemistry, computational biology, and machine learning to decode the adaptive immune system. The company offers the clonoSEQ diagnostic test, which detects and monitors minimal residual disease in cancer patients. Adaptive Biotechnologies serves the life sciences research, clinical diagnostics, and drug discovery markets.
Bottom Line
Guggenheim's reiterated buy rating reflects confidence in Adaptive Biotechnologies' growth potential, despite its current lack of profitability. Investors often track such analyst ratings closely, as they can influence market perceptions and stock movements. It's important to remember that these ratings are based on past performance and projections, and actual results may vary.
Get Adaptive Biotechnologies Corporation alerts
New 13F filings, insider trades, and analyst moves on $ADPT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.